Subscribe
shutterstock_1329494750_pavel_kapysh
Pavel Kapysh / Shutterstock.com
4 September 2019AmericasSarah Morgan

Vertex to buy diabetes biotech firm for $950m

US-based Vertex Pharmaceuticals has announced it will pay $950 million to acquire Semma Therapeutics, a biotechnology company focused on researching a cure for Type 1 diabetes.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Vertex to acquire rights to cystic fibrosis treatment for $1.6m
9 March 2017   US-based Vertex Pharmaceuticals has agreed to acquire a potential treatment for cystic fibrosis from Concert Pharmaceuticals, also in the US, for $160 million.
Americas
Vertex and CRISPR Therapeutics to develop gene-editing treatment
14 December 2017   US-based Vertex Pharmaceuticals and CRISPR Therapeutics have revealed plans to jointly develop and commercialise an investigational gene-editing treatment.


Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024

Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024
Americas
New-look WIPR Leaders 2024 is ‘most rigorous’ yet
2 July 2024
Americas
Earthquake Chevron: A massive shock to the system?
2 July 2024
Americas
Amarin wins appeal to advance ‘skinny label’ suit over Hikma generic
27 June 2024
Biotechnology
Guardant Health files suit against Tempus AI
13 June 2024
Big Pharma
Roche fires lawsuit at Sinocare unit over blood glucose test strip patents
6 June 2024

More on this story

Americas
Vertex to acquire rights to cystic fibrosis treatment for $1.6m
9 March 2017   US-based Vertex Pharmaceuticals has agreed to acquire a potential treatment for cystic fibrosis from Concert Pharmaceuticals, also in the US, for $160 million.
Americas
Vertex and CRISPR Therapeutics to develop gene-editing treatment
14 December 2017   US-based Vertex Pharmaceuticals and CRISPR Therapeutics have revealed plans to jointly develop and commercialise an investigational gene-editing treatment.

More on this story

Americas
Vertex to acquire rights to cystic fibrosis treatment for $1.6m
9 March 2017   US-based Vertex Pharmaceuticals has agreed to acquire a potential treatment for cystic fibrosis from Concert Pharmaceuticals, also in the US, for $160 million.
Americas
Vertex and CRISPR Therapeutics to develop gene-editing treatment
14 December 2017   US-based Vertex Pharmaceuticals and CRISPR Therapeutics have revealed plans to jointly develop and commercialise an investigational gene-editing treatment.

More features

Chinese biotech takes out US rival’s nucleic acid patent at PTAB
Attorney v examiner: Navigating patenting's AI tools ‘arms race’
Lewis Roca promotes tech expert to managing partner
Panitch Schwarze brings in molecular biologist
US targets ‘product hopping’ with biologic litigation curbs
UPC confirms validity of Edwards Lifesciences heart valve tech patent
ITC concludes row over biotech lab equipment between US and German rivals
UKIPO launches ‘revolutionary’ patent filing and AI tool